BioNTech SE
$20.26B- Market cap
- $26.06B
- Debt
- +$2.68B
- Cash
- −$7.68B
Capital structure 91% equity / 9% debt · EV / Revenue 6.07x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $26.06B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: BNTX stock price at premium vs PETS $103.76 current versus $2.91 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PETS's multiple
Implied fair value · at BNTX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BNTX FY 2025 (ended Dec 31, 2025) · PETS FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 91% equity / 9% debt · EV / Revenue 6.07x
Capital structure 47% equity / 53% debt · EV / Revenue 0.35x
BNTX carries the larger enterprise value at $20.26B against $62.17M; PETS trades on the lower EV / Revenue multiple (0.35x vs 6.07x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BioNTech SE · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
PETMED EXPRESS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
1.53x
Net debt / EBITDA
Leverage against operating earnings
4.45x
-0.41x
Cash and equivalents
Liquid reserves on the balance sheet
$7.68B
$21.41M
Total debt
Interest-bearing obligations outstanding
$2.68B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
BNTX vs MRNA
GILEAD SCIENCES, INC.
BNTX vs GILD
AMGEN INC
BNTX vs AMGN
REGENERON PHARMACEUTICALS, INC.
BNTX vs REGN
INCYTE CORP
BNTX vs INCY
VERTEX PHARMACEUTICALS INC / MA
BNTX vs VRTX
Chewy, Inc.
BNTX vs CHWY
Petco Health & Wellness Company, Inc.
BNTX vs WOOF
TRACTOR SUPPLY CO /DE/
BNTX vs TSCO
CENTRAL GARDEN & PET CO
BNTX vs CENT
$44.35M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.